Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: WVE) | Delayed: 3.40 +0.03 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.37 | 52 Week High | $38.50 | |||
| Open | $3.36 | 52 Week Low | $8.95 | |||
| Day High | $3.43 | P/E | N/A | |||
| Day Low | $3.35 | EPS | $0.00 | |||
| Volume | 349,652 | |||||
